Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.

ABSTRACT:

Background

Many therapies for heart failure (HF) have shown differential impact across the spectrum of left ventricular ejection fraction (LVEF).

Objectives

In this prespecified analysis, the authors assessed the effects of semaglutide across the baseline LVEF strata in patients with the obesity phenotype of HF with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) trial.

Methods

STEP-HFpEF randomized 529 patients (263 semaglutide; 266 placebo). For this prespecified analysis, patients were categorized into 3 groups based on LVEF: 45% to 49% (n = 85), 50% to 59% (n = 215), and ≥60% (n = 229).

Results

At 52 weeks, semaglutide improved the dual primary endpoints of Kansas City Cardiomyopathy Ques

SUBMITTER: Butler J 

PROVIDER: S-EPMC11185158 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature